UDP glucuronosyltransferase family 2 member B24, pseudogeneGenealiases: []
Q-omics provides the consensus-scored UGT2B24P profile across patient tissues and cancer cell-line models. UGT2B24P expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, UGT2B24P is differentially expressed in 4, with the highest sampling consensus in CHOL. Additionally, UGT2B24P RNA expression shows 6,455 significant gene co-expression associations, with the highest sampling consensus in HNSC. Together, these results highlight HNSC, and CHOL as cancer lineages where UGT2B24P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UGT2B24P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UGT2B24P survival associations across molecular data types. UGT2B24P RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UGT2B24P RNA expression–survival associations across cancer types. High UGT2B24P expression shows unfavorable associations in SKCM, OV and READ, but favorable associations in HNSC, KIRP and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for UGT2B24P RNA expression.
This table summarizes UGT2B24P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for UGT2B24P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UGT2B24P shows lower tumor expression in CHOL, KIRP and LIHC and higher tumor expression in PRAD. The CHOL box plot shows higher UGT2B24P RNA expression in normal versus tumor tissue (log2 FC = −0.596, t-test p < 0.001).
This table shows molecular features associated with UGT2B24P in patient tissues and cancer cell lines. In patient samples, UGT2B24P shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
